INFLUENCE OF THE DEFECTIVE METABOLISM OF SPARTEINE ON ITS PHARMACOKINETICS

被引：56

作者：

EICHELBAUM, M

SPANNBRUCKER, N

DENGLER, HJ

机构：

[1] Department of Medicine, University of Bonn, Bonn-Venusberg

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1979年 / 16卷 / 03期

关键词：

defective metabolism; pharmacogenetic defect; pharmacokinetics; renal excretion; sparteine;

D O I：

10.1007/BF00562060

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sparteine is metabolized by N1-oxidation, which in some subjects is defective. The defect has a pronounced effect on the kinetics of the drug. In non-metabolisers elimination of sparteine proceeds entirely via renal excretion by a capacity-limited process, 99,9% of the dose being excreted as unchanged drug. In metabolisers the drug is mainly eliminated by metabolic degradation. Pronounced differences in β-phase half-life and total plasma clearance were observed between metabolisers (156 min; 535 ml · min-1) and nonmetabolisers (409 min; 180 ml · min-1). © 1979 Springer-Verlag.

引用

页码：189 / 194

页数：6

共 9 条

[1] BINNIG F, 1974, ARZNEIMITTEL-FORSCH, V24, P752
[2] DENGLER H J, 1970, Pharmacologia Clinica, V2, P189, DOI 10.1007/BF00404298
[3] DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT
EICHELBAUM, M
SPANNBRUCKER, N
STEINCKE, B
DENGLER, HJ
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) : 183 - 187
[4] ASSESSMENT OF PHARMACOKINETIC CONSTANTS FROM POSTINFUSION BLOOD CURVES OBTAINED AFTER IV INFUSION
LOO, JCK
RIEGELMAN, S
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1970, 59 (01) : 53 - +
[5] PETERS L, 1960, PHARMACOL REV, V12, P1
[6] RENNICK BR, 1965, J PHARMACOL EXP THER, V148, P262
[7] SPANNBRUCKER N, UNPUBLISHED
[8] SPERBER I, 1949, SCAND J CLIN LAB INV, V1, P345
[9] SPITELLER M, 1978, BIOL OXIDATION NITRO, P109

← 1 →